重药控股：盐酸普拉格雷片已收到国家药品监督管理局签发的《药物临床试验批准通知书》

Core Viewpoint - The company Chongqing Pharmaceutical Holdings (重药控股) has received the clinical trial approval notice for its drug, Prasugrel Hydrochloride Tablets, from the National Medical Products Administration (NMPA) of China, indicating progress in its drug development process [1] Group 1 - The company announced on September 12 that it will soon commence clinical trials for Prasugrel Hydrochloride Tablets following the receipt of the approval notice [1] - According to Chinese drug registration laws and regulations, the drug must undergo clinical trials and receive further review and approval from the NMPA before it can be manufactured and marketed [1] - The drug development process is lengthy and involves multiple stages, making it susceptible to various uncertainties [1]